Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EP0031
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ellipses Launches Pioneering Clinical Trial Programme in Middle East
Details : EP0031 is a potent next-generation selective RET inhibitor is being investigated for the potential treatment of RET-fusion positive non-small cell lung cancer.
Product Name : EP0031
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2024
Lead Product(s) : EP0031
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EP0031
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ellipses' Next Generation Selective RET Inhibitor EP0031/A400 Cleared to Start Phase 2
Details : EP0031 is a potent next-generation selective RET inhibitor that has been granted fast track designation by the FDA for the potential treatment of RET-fusion positive non-small cell lung cancer.
Product Name : EP0031
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2024
Lead Product(s) : EP0031
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EP0031
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Kelun-Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EP0031 is a potent next generation SRI with broad activity against common RET-altered tumour and mutations, including solvent front resistance mutations.
Product Name : EP0031
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2023
Lead Product(s) : EP0031
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Kelun-Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EP0042
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ellipses Pharma: EP0042 Receives Orphan Drug Designation from the US Food and Drug Administration
Details : EP0042 is a dual FLT3 and aurora kinase inhibitor under development as a new treatment for AML patients who have developed FLT3 inhibitor resistance. Aurora kinase has been shown to overcome acquired resistance to selective FLT3 inhibition both in vitro ...
Product Name : EP0042
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : EP0042
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EP0042
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EP0042 is a dual FLT3 and Aurora kinase inhibitor under development as a new treatment for AML patients who have developed FLT3 inhibitor resistance. Aurora kinase has been shown to overcome acquired resistance to selective FLT3 inhibition both in vitro ...
Product Name : EP0042
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2023
Lead Product(s) : EP0042
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EP0031
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ellipses Announces First Patient Dosed with EP0031, a Next Generation Selective RET Inhibitor
Details : EP0031 is an SRI which aims to address the unmet need for patients with RET-altered tumours (Non-Small Cell Lung Cancer (NSCLC), medullary thyroid and other RET-altered tumours) who have progressed on first generation SRIs.
Product Name : EP0031
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2022
Lead Product(s) : EP0031
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vosilasarm
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ellipses Pharma Presents Design of Newly Initiated Phase 1/2a Trial of Vosilasarm (EP0062) at SABCS
Details : EP0062 (vosilasarm) is an oral, non-steroidal, selective androgen receptor modulator (SARM) currently being developed for the treatment of AR+/HER2-/ER+ advanced breast cancer.
Product Name : EP0062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2022
Lead Product(s) : Vosilasarm
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable